Delfi Diagnostics commercializes blood test for lung cancer screening

Walter Curran, Jr. named Whitaker Endowed Chief of Piedmont Oncology

Walter J. “Wally” Curran, Jr. has been named the Whitaker Endowed Chief of Piedmont Oncology. This bestowed title is supported by the Piedmont Foundation’s Whitaker Endowment, a fund created by the Atlanta community in tribute to Piedmont’s cancer surgical leader, William Whitaker.

March 28, 2025

Vol.51 No.12

In Brief

John Turchi named inaugural executive director of Indiana University’s Tom and Julie Wood Center for Lung Cancer

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center has named John Turchi, the inaugural executive director of the Tom and Julie Wood Center for Lung Cancer Research.

March 28, 2025

Vol.51 No.12

Clinical Roundup

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s Tagrisso (osimertinib), as monotherapy and as the backbone for novel combinations, across stages and settings of epidermal growth factor receptor-mutated non-small cell lung cancer. Highlights include:

March 28, 2025

Vol.51 No.12

Clinical Roundup

A post-treatment blood test could inform future cancer therapy decisions, study shows

In the continuing evolution of personalized medicine, a new Yale study has found evidence to support the value of a tool that measures the presence of cancer-derived molecules in the blood of patients with lung cancer years after their treatment.

March 21, 2025

Vol.51 No.11

Clinical Roundup

American College of Radiology to form early lung cancer detection registry

The American College of Radiology Lung Cancer Screening Registry is expanding and will evolve into the Early Lung Cancer Detection Registry in late 2025.

March 14, 2025

Vol.51 No.10

Clinical Roundup

Combination therapy may overcome drug resistance in lung cancer with common KRAS mutation

Scientists at VCU Massey Comprehensive Cancer Center found that combination therapy of sotorasib (Lumakras)—an FDA-approved drug in the market—and an experimental drug called FGTI-2734, could make precision medicine more effective for patients with a highly resistant form of lung cancer.

March 14, 2025

Vol.51 No.10

Delfi Diagnostics commercializes blood test for lung cancer screening

YOU MAY BE INTERESTED IN

Walter Curran, Jr. named Whitaker Endowed Chief of Piedmont Oncology

John Turchi named inaugural executive director of Indiana University’s Tom and Julie Wood Center for Lung Cancer

Study reinforces Tagrisso as the backbone therapy for EGFR-mutated lung cancer

A post-treatment blood test could inform future cancer therapy decisions, study shows

American College of Radiology to form early lung cancer detection registry

Combination therapy may overcome drug resistance in lung cancer with common KRAS mutation

Renew today!

Subscriber content

Never miss an issue!

Login